Dara BioSciences ($DARA) is the new marketer of the only orally dissolving buccal tablet approved for oral thrush, which occurs when the Candida albicans fungus grows ...

First and Only Local, Oral Prescription Formulation of Miconazole Approved for Thrush in the United States WOODCLIFF LAKE, N.J., April 16, 2010 /PRNewswire via COMTEX/ --Strativa Pharmaceuticals today ...

(RTTNews) - Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration ...

The FDA has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis in adults and childen aged 16 years and older. The drug is the first and only local, oral ...

Background and objectives: Patients with cancer, particularly those undergoing chemotherapy or radiotherapy, may develop oral mucositis. This is the first study to investigate the absorption profile ...

HONOLULU, HI—Patientswith chronic, noncancer-related pain who received fentanyl buccal tablet had consistent short-term efficacy acrossclinically meaningful analgesia measures, according to results of ...

CHARLESTON, S.C., July 21, 2014 /PRNewswire/ -- Innocutis is pleased to announce the introduction into the North American markets of Sitavig® (ACYCLOVIR) 50mg Buccal Tablet. Sitavig® (ACYCLOVIR) 50mg ...

Credit: Teva Pharmaceuticals. Teva Pharmaceuticals is recalling certain lots of Fentanyl Buccal Tablets CII because safety updates were omitted in the product insert/medication guide. Teva ...

Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG) ...

AUSTIN, TX—In a study presented at the American Pain Society’s 30th Annual Scientific Meeting, fentanyl buccal tablet (FBT) was shown to be more effective than traditional short-acting opioids (SAO) ...

This phase I, multicentre, open-label study was conducted in the US between April and September 2005. The two participating centres obtained Institutional Review Board approval and all patients ...